Apr.14.2025
R & D
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
This material is intended to notify the press release issued on April 11 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
Please clickhttps://www.bms.com/media/press-releases.html for the original press release.